Literature DB >> 11836329

Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia.

Dorle Dantz1, Jan Bewersdorf, Bernd Fruehwald-Schultes, Werner Kern, Wolfgang Jelkmann, Jan Born, Horst L Fehm, Achim Peters.   

Abstract

Glucose, the most important fuel for the brain, is supplied by the actions of counterregulatory hormones and the sympathetic nervous system. Yet to obtain access to the brain, glucose must pass the blood-brain barrier. Here we show that vascular endothelial growth factor (VEGF), a potent regulator of blood vessel function, is a candidate hormone for facilitating glucose passage across the blood-brain barrier under critical conditions. In 16 healthy men, VEGF serum concentrations increased under 6 h of insulin-induced hypoglycemic conditions from 86.1 +/- 13.4 to 211.6 +/- 40.8 pg/ml (P = 0.002), whereas in the hyperinsulinemic euglycemic control condition, no change was observed. During hypoglycemia serum VEGF, but no other counterregulatory hormone, was associated with preserved neurocognitive function, as measured with a memory test (r = 0.539; P = 0.031) and the Stroop interference task (r = 0.569; P = 0.021). Findings show that acute hypoglycemia is accompanied by a brisk increase in circulating VEGF concentration and that VEGF could mediate rapid adaptation of the brain to neuroglycopenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836329     DOI: 10.1210/jcem.87.2.8215

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Fitting background-selection predictions to levels of nucleotide variation and divergence along the human autosomes.

Authors:  Floyd A Reed; Joshua M Akey; Charles F Aquadro
Journal:  Genome Res       Date:  2005-09       Impact factor: 9.043

2.  The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease.

Authors:  Chutatip Limkunakul; Ian H de Boer; Bryan R Kestenbaum; Jonathan Himmelfarb; T Alp Ikizler; Cassianne Robinson-Cohen
Journal:  J Diabetes Complications       Date:  2019-01-07       Impact factor: 2.852

Review 3.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

Review 4.  Hypoglycemia, diabetes, and cardiovascular events.

Authors:  Cyrus V Desouza; Geremia B Bolli; Vivian Fonseca
Journal:  Diabetes Care       Date:  2010-06       Impact factor: 17.152

5.  Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men.

Authors:  Michaela Loebig; Johanna Klement; André Schmoller; Simone Betz; Nicole Heuck; Ulrich Schweiger; Achim Peters; Bernd Schultes; Kerstin M Oltmanns
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

Review 6.  Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines.

Authors:  Shalini Iyer; K Ravi Acharya
Journal:  FEBS J       Date:  2011-10-07       Impact factor: 5.542

Review 7.  Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis.

Authors:  Ana Catarina Pronto-Laborinho; Susana Pinto; Mamede de Carvalho
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

8.  Comparison of peripheral and central schizophrenia biomarker profiles.

Authors:  Laura W Harris; Sandra Pietsch; Tammy M K Cheng; Emanuel Schwarz; Paul C Guest; Sabine Bahn
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

9.  Clinical improvement after treatment with VEGF(165) in patients with severe chronic lower limb ischaemia.

Authors:  Andrei Anghel; Bogdan Mut-Vitcu; Lorand Savu; Catalin Marian; Edward Seclaman; Raluca Iman; Adriana-Maria Neghina; Stefan I Dragulescu
Journal:  Genomic Med       Date:  2007-05-25

10.  Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression.

Authors:  Dimitrios Panutsopulos; Alexandros Zafiropoulos; Elias Krambovitis; George E Kochiadakis; Nikos E Igoumenidis; Demetrios A Spandidos
Journal:  J Transl Med       Date:  2003-10-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.